Sebetralstat

Oral medication for hereditary angioedema

Sebetralstat
[[File: Chemical structure of Sebetralstat |frameless|220px|alt=|]]
INN
Drug class
Routes of administration	Oral
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status	Investigational
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Sebetralstat is an investigational oral medication developed for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of severe swelling. Sebetralstat is designed to be a fast-acting treatment option for acute attacks of HAE, providing relief by inhibiting the activity of plasma kallikrein, an enzyme involved in the production of bradykinin, which is responsible for the swelling and pain associated with HAE attacks.

Mechanism of Action

Sebetralstat functions as a selective inhibitor of plasma kallikrein. Plasma kallikrein is a key enzyme in the kinin-kallikrein system, which, when activated, leads to the production of bradykinin. Bradykinin is a potent vasodilator that increases vascular permeability, leading to the characteristic swelling seen in HAE. By inhibiting plasma kallikrein, sebetralstat reduces the production of bradykinin, thereby mitigating the symptoms of an HAE attack.

Clinical Development

Sebetralstat is currently undergoing clinical trials to evaluate its efficacy and safety in patients with hereditary angioedema. The drug is being developed by KalVista Pharmaceuticals, and it is known by the investigational name KVD900. Early clinical studies have shown promising results, with rapid onset of action and significant reduction in attack severity and duration.

Administration

Sebetralstat is administered orally, which offers a convenient alternative to injectable therapies currently available for HAE. The oral route of administration is particularly advantageous for patients who require immediate treatment during an acute attack, as it allows for rapid self-administration without the need for medical supervision.

Potential Benefits

The development of sebetralstat as an oral therapy for HAE represents a significant advancement in the management of this condition. The potential benefits include:

• Rapid onset of action, providing quick relief from symptoms.
• Ease of administration, improving patient compliance and quality of life.
• Reduction in the frequency and severity of HAE attacks.

Related pages

• Hereditary angioedema
• Plasma kallikrein
• Bradykinin
• KalVista Pharmaceuticals